Dual‐regulated expression of C/EBP‐α and BMP‐2 enables differential differentiation of C2C12 cells into adipocytes and osteoblasts by Fux, Cornelia et al.
Dual-regulated expression of C/EBP-a and BMP-2
enables differential differentiation of C2C12 cells into
adipocytes and osteoblasts
Cornelia Fux, Barbara Mitta, Beat P. Kramer and Martin Fussenegger*
Institute of Biotechnology, Swiss Federal Institute of Technology, ETH Hoenggerberg, HPT D74, CH-8093 Zurich,
Switzerland
Received July 9, 2003; Revised October 20, 2003; Accepted November 3, 2003
ABSTRACT
CCAAT/enhancer-binding proteins (C/EBPs) as well
as bone morphogenic proteins (BMPs) play essen-
tial roles in mammalian cell differentiation in
shaping adipogenic and osteoblastic lineages in
particular. Recent evidence suggested that adipo-
cytes and osteoblasts share a common mesenchy-
mal precursor cell phenotype. Yet, the molecular
details underlying the decision of adipocyte versus
osteoblast differentiation as well as the involvement
of C/EBPs and BMPs remains elusive. We have
engineered C2C12 cells for dual-regulated expres-
sion of human C/EBP-a and BMP-2 to enable inde-
pendent transcription control of both differentiation
factors using clinically licensed antibiotics of
the streptogramin (pristinamycin) and tetracycline
(tetracycline) classes. Differential as well as co-
ordinated expression of C/EBP-a and BMP-2
revealed that (i) C/EBP-a may differentiate C2C12
myoblasts into adipocytes as well as osteoblasts,
(ii) BMP-2 prevents myotube differentiation, (iii) is
incompetent in differentiating C2C12 into osteo-
blasts and (iv) even decreases C/EBP-a's osteo-
blast-speci®c differentiation potential but (v)
cooperates with C/EBP-a on adipocyte differenti-
ation, (vi) osteoblast formation occurs at low
C/EBP-a levels while adipocyte-speci®c differenti-
ation requires maximum C/EBP-a expression and
that (vii) BMP-2 may bias the C/EBP-a-mediated
adipocyte versus osteoblast differentiation switch
towards fat cell formation. Dual-regulated expres-
sion technology enabled precise insight into com-
binatorial effects of two key differentiation factors
involved in adipocyte/osteoblast lineage control
which could be implemented in rational reprogram-
ming of multipotent cells into desired cell pheno-
types tailored for gene therapy and tissue
engineering.
INTRODUCTION
Mesenchymal stem cells are multipotent cells which can
differentiate into adipocyte, chondrocyte, myoblast and
osteoblast lineages (1±4). Recent evidence suggested that
adipocytes and osteoblasts originate from a common mesen-
chymal precursor cell (5), which raises particular interest on
how molecular lineage control is implemented in those cells.
CCAAT/enhancer-binding proteins (C/EBPs) comprise a
family of transcription factors that have key metabolic and
differentiation missions in many tissues (6±8). To date, six
members of the C/EBP family (C/EBP-a, -b, -d, -g, -e, -z)
have been identi®ed, which are expressed in various cell types
including adipocytes and osteoblasts (9±11). All C/EBPs share
a highly conserved DNA-binding domain as well as a bZIP
dimerization domain (12,13), which enables homo- and
heterodimeric binding to sequence-speci®c operators (14,
15). While ectopic expression of C/EBP-a was suf®cient for
differentiation of mouse ®broblasts into adipocytes (16), fat-
cell-speci®c differentiation of G8 mouse myoblasts required
coordinated expression of C/EBP-a and PPARg (a member of
the nuclear hormone receptor family) as well as addition of
diverse lipids and/or lipid-like compounds including
5,8,11,14-eicosatetrayonic acid (ETYA) to the culture
medium (17±19).
Previous studies have implied that the bone morphogenic
protein 2 (BMP-2) promotes osteoblast-speci®c differentiation
of C2C12 myoblasts via induction of several osteogenic
master transcription factors including Runx2 and Osterix (20±
23). BMP-2 belongs to the transforming growth factor b
family of differentiation factors that play key roles in
chondrogenic or osteogenic lineage control, bone remodeling
as well as differentiation of mesenchymal cells (24,25).
However, BMP function seems not to be restricted to bone or
cartilage formation since some family members have been
found (i) to prevent myotube differentiation of myoblasts (26),
(ii) to commit pluripotent mouse ®broblast cells (C3H10T1/2)
to osteoblasts, chondroblasts and adipocytes (27±29) and
(iii) to stimulate adipocyte formation of mesenchymal
precursor cells (30).
Based on recent advances in heterologous transcription
control technology, we have designed dual-regulated expres-
sion con®gurations which enable independent regulation of
two different transgenes (31±37). Pioneering dual-regulated
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expression technology combined two compatible gene regu-
lation systems, the streptogramin-(PIP) and tetracycline-
(TET) responsive transgene control con®gurations which
follow a similar design concept (38): a Streptomyces
coelicolor/Escherichia coli antibiotic resistance response
regulator (Pip [pristinamycin-induced protein]/TetR) fused
to a mammalian transactivation domain (VP16) (39) recon-
stitutes a streptogramin-/tetracycline-dependent transactivator
(PIT/tTA) that binds and activates speci®c promoters [PPIR/
PhCMV*-1; assembled from Pip-/TetR-speci®c tandem operator
sites (ptr/tetO) and minimal eukaryotic promoters (PhCMVmin)]
in a pristinamycin-/tetracycline-adjustable manner (38).
Whereas in the presence of pristinamycin/tetracycline, PIT/
tTA fails to bind and transactivate PPIR/PhCMV*-1, desired
transgene expression is fully induced in the absence of
regulating antibiotics (34,38). Combination of PIP and TET
systems enabled four different digital expression con®gur-
ations: ON/ON, OFF/ON, ON/OFF and OFF/OFF (34,36,
37,40).
In this study we used dual-regulated expression of C/EBP-a
and BMP-2 for rational reprogramming of C2C12 to reveal
mechanisms underlying C2C12 to adipocyte and C2C12 to
osteoblast differentiation. Multiregulated multigene-based
therapeutic interventions as presented here are expected to
enable design of desired cell phenotypes for gene therapy and
tissue engineering in the not-too-distant future.
MATERIALS AND METHODS
Vector constructions
pCF141 was constructed by excising human C/EBP-a
[pCMVa (41)] from pCF50 (pAI-C/EBPa¬PhCMV*-1-stuffer-
PPIR8®E7-HA-pAII; C.Fux et al., unpublished) using BamHI/
ClaI and cloning it into the corresponding sites (BamHI/ClaI)
of pCF93 (PhCMV*-1-MCS-pAI-PPGK-puro-pAII; C.Fux,
unpublished) to result in pCF141 (PhCMV*-1-C/EBPa-pAI-
PPGK-puro-pAII). pCF240 was constructed following a two
step procedure: (i) C-terminally hemagglutinin A (HA)-
tagged human BMP-2 (BMP-2-HA) was constructed by
amplifying BMP-2 cDNA (W.Weber, unpublished) using
oligonucleotides OWW15: 5¢-ggaagcttgaattcCCACCATG-
GTGGCCGGGACCCGC-3¢ (annealing sequence upper
case, HindIII and EcoRI sites underlined) and OWW16:
5¢-ggagatctgaattcatttaaatTCAAGCGTAATCTGGAACA-
TCGTATGGGTAgcgacacccacaaccctccacaac-3¢ (annealing
sequence upper case, BglII, EcoRI and SwaI sites underlined,
HA-Tag in italic) followed by subsequent cloning in sense
orientation into pEF6/V5-His TOPO (Invitrogen, Carlsbad,
CA) to create pWW16. (ii) BMP-2-HA was excised from
pWW16 using EcoRI and cloned into the corresponding site
(EcoRI) of pCF217 (PPPI8-MCS-pAI-PPGK-zeo-pAII; C.Fux,
unpublished) to give pCF240 (PPPIR8-BMP2-HA-pAI-PPGK-
zeo-pAII). Lentivector pBP252 was constructed by excising C/
EBP-a from pCF257 by EcoRI/StuI and ligating it into the
EcoRI/SwaI of pMF359 (42). Likewise, BMP-2 was excised
from pCF241 using EcoRI/MluI and cloned into EcoRI/MluI-
restricted pMF359 to give pBP253. Details on pCF257 and
pCF241 are available upon request.
Cell culture, transfection, lentiviral particle production
and transduction
Wild-type C2C12 (C2C12, ATCC:CRL-1772) were cultivated
in Dulbecco's modi®ed Eagle's medium (DMEM, Invitrogen,
Carlsbad CA) supplemented with 10% FCS (PAA
Laboratories GmbH, Linz, Austria; catalog no. A15-022, lot
no. A01129-242) (basic medium). The cell line C2C12PIT/tTA
stably expressing the streptogramin-(PIT) and the tetra-
cycline-(tTA) dependent transactivators was cultivated in
basic medium that also contained 800 mg/ml G418. The cell
line C2C12PIT/tTA-C/EBPaTET, a C2C12PIT/tTA derivative
harboring a tetracycline-responsive CEBP-a expression unit
(pCF141; PhCMV*-1-CEBPa-pAI-PPGK-puro-pAII) was culti-
vated in basic medium supplemented with 800 mg/ml G418
and 1 mg/ml puromycin. The cell line C2C12PIT/tTA-
CEBPaTET-BMPPIP, a C2C12PIT/tTA-C/EBPaTET engineered
for streptogramin-responsive BMP2 expression (pCF240;
PPIR8-BMP2-HA-pAI-PPGK-zeo-pAII) was cultivated in
medium supplemented with 800 mg/ml G418, 1 mg/ml
puromycin and 40 mg/ml zeocin. Transfection of C2C12
derivates was performed using a modi®ed CaPO4-based
protocol (32). 120 000 cells per 6 well were transfected with
1.2 mg DNA, which resulted in a typical transfection ef®ciency
of 40 6 5%. Production and transduction protocols using
replication-incompetent self-inactivating lentiviral particles
have been described before (42).
Construction of stable cell lines
The stable cell line C2C12PIT/tTA-CEBPaTET was generated
by transfection of pCF141 (PhCMV*-1- C/EBPa-pAI-PPGK-
puro-pAII) into C2C12PIT/tTA. The mixed stable population
was selected for 3 weeks in basic medium supplemented with
selective (800 mg/ml G418, 1 mg/ml puromycin) and regulat-
ing (5 mg/ml tetracycline) antibiotics prior to FACS-mediated
single-cell sorting. Similarly, stable cell line C2C12PIT/tTA-
CEBPaTETBMP2PIP was produced by transfecting pCF240
(PPIR8-BMP-HA-pAI-PPGK-zeo-pAII) into C2C12PIT/tTA-
CEBPaTET followed by a 3-week expansion of a stable
mixed population in medium supplemented with various
selective and regulating antibiotics (800 mg/ml G418, 1 mg/ml
puromycin, 40 mg/ml zeocin, 5 mg/ml tetracycline and 2 mg/ml
pristinamycin) prior to FACS-meditated single-cell cloning.
Western blot analysis
For preparation of whole cell extracts, cells were washed with
ice-cold PBS and scraped into lysis buffer (Roche Diagnostics
AG, Basel, Switzerland). Cells were allowed to lyse for 15 min
prior to centrifugation of the lysates for 20 s at 23 000 g.
Protein concentrations of whole cell extracts were determined
using a BCAÔ Protein Assay (SOCOCHIM, Lausanne,
Switzerland). Prior to resolution on a 12% polyacrylamide
gel, proteins mixtures contained in whole cell extracts and cell
culture supernatants were denatured by boiling for 10 min in
sample buffer (10% glycerol, 50 mM Tris±HCl, 1% SDS and
0.005% bromophenol blue). Proteins were then blotted onto
polyvinylidene di¯uoride (PVDF) membranes (Millipore,
Bedford, MA), which were subsequently blocked using 5%
non-fat dry milk in TTBS (50 mM Tris, pH 7.5, 150 mM NaCl,
0.05% Tween-20). Blots were probed with speci®c primary
antibodies (C/EBPa: Santa Cruz, 14AA, catalog no. sc-61, lot
e1 Nucleic Acids Research, 2004, Vol. 32, No. 1 PAGE 2 OF 9
no. F080; HA-probe: Santa Cruz, Y-11; catalog no. sc-805, lot
no. G070) and visualized using an appropriate horseradish
peroxidase-coupled secondary antibody (Amersham, catalog
no. NA934V, lot no. 211112) linked to an ECL detection
readout (Amersham, Buckinghamshire, UK; catalog no. RPN
2106).
Characterization of cell phenotypes
In order to visualize adipogenic cell phenotypes, cells were
cultured to 80% con¯uence in basic medium and then
transferred to medium supplemented with 1 mM dexametha-
sone, 5 mg/ml insulin and 50 mM ETYA [Dex/ETYA/Insulin,
DEI; (19)]. Fourteen days post-DEI induction, the cells were
®xed in a 3.7% aqueous formaldehyde solution 1 h. Excess
formaldehyde was removed by rinsing three times 30 s with
ddH2O prior to immersion of cells for 30 min with an Oil Red
O working solution. Subsequently, the cells were washed three
times with ddH2O for 30 s and the nuclei were stained for 60 s
with Mayer's haematoxylin (Sigma Chem. Co., St Louis,
MO). Finally, the cells were rinsed in ddH2O for 10 min and
covered with a coverslip using 10% glycerol in PBS (43).
Alkaline phosphatase-speci®c staining of osteogenic cell
phenotypes was visualized following a 5-day cultivation
using the Sigma Kit 85 according to the manufacturer's
instructions (Sigma Chem. Co., St Louis, MO).
Antibiotics and chemicals
Pyostacinâ pills (500 mg; Aventis Inc., France; lot no. 27404)
were ground in a mortar and dissolved in DMSO (50 mg/ml).
Alternatively, antibiotic discs containing 15 mg pristinamycin
(bioMeÂrieux, Geneva, Switzerland) were soaked in 7.5 ml 4°C
cell culture medium for 30 min. Pristinamycin I (PI) (2 mg/ml)
was routinely used for regulation studies in cell culture and
calculated based on the ®xed 70:30 ratio (w/w) of the non-
regulating pristinamycin II and PI in the composite antibiotic
pristinamycin (44). Pyostacin- or antibiotic disc-derived PI
was as ef®cient in regulating streptogramin-responsive
expression systems as the pure PI reference compound kindly
provided by Aventis Inc. (RP27404, lot no. SOU2890IICA;
France). G418 was obtained form Calbiochem-Novabiochem
Inc. (La Jolla, CA), puromycin from ALEXIS Inc. (San Diego,
CA), zeocin from Invitrogen (Carlsbad, CA) and tetracycline
from Sigma Chemicals (St Louis, MO). Dexamethasone was
purchased from Fluka Chemie (Buchs SG, Switzerland),
insulin and ETYA from Sigma Chemicals (St Louis, MO). For
an Oil Red O (Fluka Chemie, Buchs SG, Switzerland) stock
solution 500 mg Oil Red O were dissolved in 100 ml 60%
triethyl-phosphate (Fluka Chemie, Buchs SG, Switzerland).
Prior to staining, a 36% triethyl-phosphate working solution
containing 12 ml Oil Red O stock solution and 8 ml ddH20 was
prepared. Puri®ed human BMP-2 was purchased from
PeproTech EC Ltd (London, UK) and used at concentrations
of 3 ng/ml.
RESULTS
Production of C2C12 cells engineered for
tetracycline-responsive C/EBP-a expression
In order to enable tetracycline-responsive expression of
C/EBP-a in C2C12 cells we transduced this cell line with
pRetroTWIN3-derived retroviral particles encoding the tetra-
cycline-dependent as well as the pristinamycin-dependent
transactivators. Resulting C2C12PIT/tTA was stably transfected
with pCF141, which contains human C/EBP-a under control
of the tetracycline-responsive promoter (PhCMV*-1) and
encodes a puromycin resistance-conferring gene driven by
the constitutive phosphoglycerate kinase promoter (PPGK)
(Fig. 1A). In order to prevent any differentiation/growth bias,
C/EBP-a expression was repressed by addition of tetracycline
during the entire selection and cloning procedures. Two
randomly chosen C2C12PIT/tTA-CEBPaTET clones (numbers 1
and 45) showed tetracycline-responsive C/EBP-a expression
pro®les (Fig. 1B). Also, both cell clones differentiated into
myotubes when C/EBP-a was repressed by addition of
tetracycline while myotube formation was repressed following
cultivation of C2C12PIT/tTA-CEBPaTET under C/EBP-a-
induced and low serum conditions (data not shown). These
®ndings support an earlier report correlating C/EBP-a
expression and low-serum cultivation of G8 myoblasts with
inhibition of myotube-speci®c differentiation (19).
C/EBP-a is suf®cient to convert C2C12 cells into
adipocytes
Previous initiatives to differentiate G8 myoblasts into
adipocytes required concomitant expression of C/EBP-a and
PPARg as well as addition of DEI to the culture medium.
Either of the two determinants alone was not suf®cient for
adipocyte commitment of this muscle cell type (19). In order
to assess the potential of C2C12PIT/tTA-CEBPaTET cells to
differentiate into adipocytes we cultivated this cell line for 14
days in DEI-containing medium in the presence (+Tet; C/
EBP-a repressed) and absence of tetracycline (±Tet; C/EBP-a
induced) prior to Oil Red O-mediated staining of adipocyte-
speci®c triglyceride droplets. Both C2C12PIT/tTA-CEBPaTET
clones showed increased adipocytic lineage commitment
following sustained expression of C/EBP-a (Fig. 1C). In the
control settings consisting of C2C12PIT/tTA-CEBPaTET culti-
vated in the presence of tetracycline or the parental cell line
C2C12PIT/tTA no adipogenic cell phenotypes could be
observed (Fig. 1C). Likewise, transduction of C2C12 wild-
type cells with lentiviral particles engineered for constitutive
C/EBP-a expression induced adipocyte-speci®c differenti-
ation in contrast to control transductions using isogenic
lentiviral particles (Fig. 1D). Despite their equivalence, clone
C2C12PIT/tTA-CEBPaTET45 was used for further analysis.
Design of a C2C12-derived cell line transgenic for
dual-regulated expression of human CEBP-a and
BMP-2
Dual-regulated expression technology enables independent
control of two different transgenes (34,36,37). We have
engineered C2C12 cells for tetracycline-responsive expression
of human CEBP-a as well as streptogramin-responsive
expression of the human BMP-2. Therefore, C2C12PIT/tTA-
CEBPaTET45 was stably transfected with pCF240 which
provides streptogramin-responsive expression of BMP-2-HA
and enables selection for zeocin (Fig. 2A). Two randomly
chosen cell clones C2C12PIT/tTA-CEBPaTET-BMP2PIP2 and
C2C12PIT/tTA-CEBPaTET-BMP2PIP6 showed independent
regulation of BMP-2 and CEBP-a following 5-day cultivation
of engineered cells in media supplemented with different
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combinations of regulating pristinamycin and tetracycline
antibiotics (Fig. 2B).
BMP-2 cooperates with C/EBP-a on conversion of
C2C12 into adipocytes
Recent reports associated BMP-2 with promoting
adipogenic differentiation of the murine pre-adipocyte cell
line 3T3-L1 following coexpression with peroxisome pro-
liferator-activated receptor gamma (PPARg) (30). In order
to evaluate the potential of BMP-2 to differentiate C2C12
cells into adipocytes, C2C12PIT/tTA-CEBPaTET-BMPPIP2
and C2C12PIT/tTA-CEBPaTET-BMPPIP6 (C2C12PIT/tTA-
CEBPaTET-BMPPIP2/6) were cultivated for 12 days in
DEI-containing medium supplemented with different cock-
tails of regulating antibiotics: ±Tet/±PI, ±Tet/+PI, +Tet/±PI
and +Tet/+PI. Adipocyte-speci®c Oil Red O staining revealed
increased adipocyte formation in the ±Tet/±PI combination
(C/EBP-a and BMP-2 expressed; Fig. 3A and E) compared to
Figure 1. C/EBPa expression of C2C12PIT/tTA cells stably transfected with pCF141 (C2C12PIT/tTA-CEBPaTET). (A) Schematic representation of pCF141.
pCF141 encodes human C/EBP-a under control of the tetracycline-responsive promoter (PhCMV*-1). The gene conferring resistance to puromycin (puro) is
driven by the constitutive phosphoglycerate kinase promoter (PPGK). Polyadenylation sites are indicated (pA1, pAII). (B) Western blot analysis of whole-cell
extracts (20 mg total protein) of C2C12PIT/tTA-CEBPaTET1 and C2C12PIT/tTA-CEBPaTET45 grown for 5 days in the presence (+Tet) and absence (±Tet) of
tetracycline. The parental cell line C2C12PIT/tTA was used as a control. (C) Adipocyte-speci®c differentiation of C2C12 cell derivatives following tetra-
cycline-responsive expression of C/EBP-a. (D) Adipocyte-speci®c differentiation of C2C12 wild-type cells after transduction of lentiviral particles engineered
for constitutive C/EBP-a expression (pBP252) or isogenic control lentiviruses (pMF359). Oil Red O-mediated staining of triclyceride droplets of C2C12
derivatives cultivated for 14 days in DEI-containing medium supplemented with tetracycline where indicated (C and D).
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the ±Tet/+PI (only C/EBP-a expressed; Fig. 3B and F)
con®guration suggesting that BMP-2 cooperates with C/EBP-
a for maximum adipocyte commitment compared to ±Tet/
+PI (only C/EBP-a expressed; Fig. 3B and F). Clone
C2C12PIT/tTA-CEBPaTET-BMPPIP6 showed less prominent
adipocyte differentiation compared to C2C12PIT/tTA-
CEBPaTET-BMPPIP2 which correlates with its lower maxi-
mum BMP-2 expression levels (see Fig. 2B). Interestingly,
following exclusive BMP-2 expression no adipogenic
differentiation could be observed in either of the two cell
clones (Fig. 3C and G). Likewise, no fat cells were detected
for the +Tet/+PI setting when both genes were not expressed
(Fig. 3D and H).
Differential lineage control of a C2C12-derived cell line
engineered for independent control of C/EBP-a and
BMP-2
BMP-2 has ®rst been identi®ed as a factor that induces bone
and cartilage formation (23,26,45,46). We have assessed the
potential of C2C12PIT/tTA-CEBPaTET-BMPPIP2/6 to form
osteoblasts following growth for 5 days in medium containing
different combinations of regulating tetracycline and pristi-
namycin antibiotics (±Tet/±PI, ±Tet/+PI, +Tet/±PI and +Tet/
+PI). Speci®c staining for the osteogenic alkaline phosphatase
(ALP) revealed highest osteoblast formation following exclu-
sive expression of C/EBP-a (±Tet/+PI) (Fig. 4B and F).
Coordinated expression of C/EBP-a and BMP-2 resulted in
reduced osteoblast-speci®c differentiation (Fig. 4A and E).
Expression of BMP-2 (+Tet/±PI) failed to induce osteogenic
differentiation in C2C12PIT/tTA-CEBPaTET-BMPPIP2/6 cells,
yet prevented myotube formation (Fig. 4C and G). In
the control con®guration in which transgene expression
was silenced by addition of both regulating antibiotics,
C2C12PIT/tTA-CEBPaTET-BMPPIP2/6 retained its C2C12
typical cell morphology (+Tet/+PI) (Fig. 4D and H). In
order to con®rm our ®nding that BMP-2 blocks myotube
formation in C2C12 cells we cultivated C2C12 wild-type cells
for 5 days in medium containing 100 ml/ml supernatant of
C2C12PIT/tTA-CEBPaTET-BMPPIP2/6 cultivated under BMP-2-
induced conditions or of C2C12 wild type as control. BMP2-
mediated inhibition of myotube formation was also observed
following transduction of C2C12 with BMP-2-encoding
lentiviral particles or addition of puri®ed BMP-2 to C2C12
wild-type cultures (Fig. 5). BMP-2 seems to set C2C12
cells for adipocyte differentiation as it blocks or reduces
commitment of myoblasts for myotubes and osteoblasts.
Dose-dependence of C/EBP-a-induced adipocyte versus
osteoblast differentiation
The capacity of C/EBP-a to induce adipocytes as well as
osteoblasts raised the question of how lineage decision is
implemented. In order to establish a direct correlation between
C/EBP-a levels and osteoblast as well as adipocyte formation
we cultivated C2C12PIT/tTA-CEBPaTET45 for 5 days in
medium supplemented with increasing tetracycline concen-
trations and scored adipocyte as well as osteoblast differen-
tiation as a consequence of different C/EBP-a dosing. Figure 6
shows dose-dependent osteoblast formation starting at low
C/EBP-a levels while adipogenesis requires maximum
expression of this differentiation factor. This ®nding suggests
that C/EBP-a mediates osteoblast-speci®c differentiation at
low and differentiation of fat cells at high intracellular
concentrations.
DISCUSSION
Mesenchymal precursor cells can differentiate into adipo-
cytes, chondrocytes, myoblasts and osteoblasts following a
program which remains elusive in many cell types. Based on
C2C12 cells engineered for dual-regulated expression of
C/EBP-a and BMP-2, we studied single as well as
combinatorial gene expression impact on the differentiation
Figure 2. C2C12 cells (C2C12PIT/tTA-CEBPaTET-BMPPIP) engineered for pristinamycin-responsive expression of human BMP-2. (A) Diagram pCF240
encoding HA-tagged BMP-2 (BMP2-HA) under control of an optimized streptogramin-responsive promoter (PPIR8) and a zeocin resistance-conferring gene
(zeo) driven by the phosphoglycerate kinase promoter (PPGK). (B) BMP-2- and C/EBP-a-speci®c western blot analysis of 20 ml culture supernatants (60/20 mg
total protein [BMP-2/C/EBP-a]) derived from C2C12PIT/tTA-CEBPaTET-BMPPIP2 and C2C12PIT/tTA-CEBPaTET-BMPPIP6 clones cultivated for 5 days in the
presence (+) or absence (±) of different combinations of tetracycline (T) and pristinamycin (PI) antibiotics. The parental cell line C2C12PIT/tTA was used as
control.
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of myoblasts into adipocytes or osteoblasts. Dual-regulated
expression enabled gene-function correlations of four differ-
ent expression con®gurations (C/EBP-aON/BMP-2ON;
C/EBP-aOFF/BMP-2ON; C/EBP-aON/BMP-2OFF; C/EBP-
aOFF/BMP-2OFF).
Previously, differentiation of myoblasts (G8 type) into
adipocytes required coordinated expression of C/EBP-a and
PPARg as well as addition of fatty acids and adipogenic
hormones to the culture medium (19). G8 myoblasts exclu-
sively expressing C/EBP-a failed to differentiate into
adipocytes and muscle-speci®c differentiation was prevented
by repression of myogenic factors. In contrast, the mutant
C2C12 cell line C2C12N supported development of fat cell
precursor cells following cultivation in medium supplemented
with fatty acids and thialidinediones (47). To date, only
®broblasts differentiated into adipocytes following ectopic
expression of C/EBP-a (16). We have demonstrated C/EBP-
a-mediated myoblast to adipocyte transition of C2C12 in the
presence of DEI.
Besides C/EBPs, BMPs play key roles during adipocyte-
and osteoblast-speci®c differentiation processes (20,22,48).
BMP-2 was reported to stimulate adipocyte differentiation of
2T3 and 3T3-L1 cells (5,30). In both cell lines BMP-2-
mediated fat cell formation required activation of PPARg
induced by addition of PPARg ligand to the culture medium.
We have shown that BMP-2 cooperated with C/EBP-a for
increased fat cell differentiation of C2C12 cell derivatives
grown in DEI-containing medium. BMP-2-boosted adipocyte
differentiation of C/EBP-a-expressing C2C12 cells was dose-
dependent since clones expressing increased BMP-2 levels
committed to fat cells at a higher frequency. Based on its name
BMP-2 was expected to rather drive osteogenic differentiation
of C2C12 than adipocyte lineage control (26). In fact,
transgenic C2C12 cells set for BMP-2 expression did not
differentiate into bone cells as did C2C12 cells grown in
supernatants of BMP-2-producing cell lines. Yet, BMP-2 was
active and inhibited myotube formation in C2C12 cells. This
unexpected ®nding may either represent a new function of the
Figure 4. Osteoblast-speci®c differentiation of C2C12 clones expressing different combinations of C/EBP-a and BMP-2. C2C12PIT/tTA-CEBPaTET-BMPPIP2
and C2C12PIT/tTA-CEBPaTET-BMPPIP6 were grown for 5 days in medium supplemented with different combinations of regulating tetracycline (Tet) and
streptogramin (PI) and stained for osteoblast-speci®c expression of alkaline phosphatase. (A and E), ±Tet/±PI; (B and F), ±Tet/+PI; (C and G), +Tet/±PI;
(D and H), +Tet/+PI.
Figure 3. Adipogenic differentiation of C2C12 derivatives following different C/EBP-a and BMP-2 expression pro®les. Adipocyte formation of C2C12PIT/
tTA-CEBPaTET-BMPPIP2 (A±D) and C2C12PIT/tTA-CEBPaTET-BMPPIP6 (E±H) cell clones cultivated for 14 days in medium containing different combinations
of regulating tetracycline (Tet) and streptogramin (PI) antibiotics. (A and E), ±Tet/±PI; (B and F), ±Tet/+PI; (C and G), +Tet/±PI; (D and H), +Tet/+PI.
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master differentiation regulator BMP-2 and/or results from
integration of mutual interference between BMP-2-/C/EBP-a
regulatory networks.
Recently, BMP-2 was reported to differentially trigger
adipocyte and osteoblast differentiation via different BMP
receptor isoforms IA and IB, respectively (5). The fact that
C2C12 cells express type IA BMP receptors (49) substantiates
our ®nding of synergistic BMP-2/C/EBP-a-mediated
induction of fat cell formation in myoblasts.
Analysis of C2C12PIT/tTA-CEBPaTET-BMPPIP2/6 capacity
to differentiate into bone cells when cultivated in different
C/EBP-a and BMP-2 expression con®gurations revealed
maximum osteoblast formation following exclusive expres-
sion of C/EBP-a, while the osteoblast frequency decreased
following coexpression of BMP-2. Similar to the situation in
ST-2 stromal cells, BMP-2 may reduce endogenous C/EBP-a
levels and therefore bias differentiation against osteoblasts
(50). Although expression of C/EBP family members has been
reported for various cell lines, including adipocytes and
osteoblasts in which they function as transactivators for
bone-speci®c osteocalcin expression (11,50), this is, to our
knowledge, the ®rst time that C/EBP-a-induced osteoblast-
speci®c differentiation could be shown. C/EBP-a's potential
to induce differentiation into adipocytes as well as osteoblasts
raises questions on how a particular lineage commitment is
controlled. C/EBP-a dose-differentiation pro®les revealed
Figure 5. BMP-2-mediated inhibition of myotube formation in C2C12 cells.
C2C12 wild-type cells were grown to con¯uence and then cultivated for
5 days in standard medium (A), in conditioned medium containing BMP-2
produced by C2C12PIT/tTA-CEBPaTET-BMPPIP2 (B), in conditioned medium
derived from C2C12 PIT/tTA (C), followed by transduction with BMP-2-
encoding lentiviral particles (D), supplemented with puri®ed BMP-2
(3 ng/ml) (E). All cultures were stained for osteo-speci®c alkaline phosphat-
ase expression. While BMP-2 fails to induce osteoblasts it inhibits myotube
formation typical for C2C12 differentiation.
Figure 6. Dose-dependence of C/EBP-a-mediated osteoblast versus adipo-
cyte lineage control. C2C12PIT/tTA-CEBPaTET45 was grown for 5 days at
increasing tetracycline concentrations correlating with decreased C/EBP-a
expression pro®les. Osteoblast-speci®c differentiation was assessed by
alkaline phosphatase staining while adipocytes were visualized by Oil Red
O-mediated staining of triglycerides.
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that osteoblast-speci®c differentiation occurs at lower C/EBP-
a levels while adipocyte formation only takes place at
maximum C/EBP-a expression. This ®nding suggests that
C/EBP-a triggers osteoblast versus adipocyte differentiation
in a dose-dependent manner. In addition, BMP-2 may reduce
C/EBP-a-mediated osteoblast differentiation and bias lineage
control towards adipocytes.
Our study demonstrated that C/EBP-a plays an important
role in adipocyte- and osteoblast-speci®c differentiation of
myoblasts and that this lineage control switch is modulated by
BMP-2. Novel insight into fat±muscle±bone transdifferen-
tiation my pave the way towards rational reprogramming
of desired cell phenotypes for gene therapy and tissue
engineering.
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